Regeneron, AstraZeneca gives mixed results on their covid-antibody cocktails against omicron

However, AstraZeneca said that a laboratory study of Evusheld, the company’s cocktail of antibodies to coronavirus, found that the treatment “retained neutralizing activity” against omicron. The study, conducted by independent investigators with the Food and Drug Administration, adds “the growing body of preclinical evidence showing that Evusheld retains activity against all tested variants of concern to date,” according to AstraZeneca.